Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.
RedHill Biopharma Ltd (NASDAQ: RDHL) is a specialty biopharmaceutical leader focused on gastrointestinal and infectious disease therapies. This page provides investors and industry professionals with comprehensive updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements including FDA submissions, clinical trial results, and partnership agreements. Track progress across RedHill’s commercial products like Talicia for H. pylori and Aemcolo for travelers’ diarrhea, along with late-stage candidates such as opaganib in oncology and inflammatory diseases.
Our curated news collection enables informed decision-making by consolidating material events including earnings reports, intellectual property updates, and research collaborations. Content spans therapeutic area breakthroughs, management commentary, and market expansion activities.
Bookmark this page for streamlined access to verified RedHill Biopharma updates. Check regularly for developments impacting the company’s position in gastrointestinal therapeutics and pandemic preparedness research.
RedHill Biopharma Ltd. (NASDAQ:RDHL) completed an $8 million underwritten public offering, led by Aegis Capital Corp. as the sole bookrunner. The funds are aimed at supporting RedHill's ongoing clinical development programs, including RHB-204 for pulmonary NTM disease and opaganib for COVID-19 and oncology treatments. This offering aligns with RedHill's focus on gastrointestinal and infectious diseases, enhancing its potential for market growth and development of innovative therapies.
RedHill Biopharma (Nasdaq: RDHL) has successfully closed an underwritten public offering, generating approximately $8.0 million in gross proceeds. The offering comprised 32 million units, each priced at $0.25, including one American Depositary Share (ADS) and one warrant to purchase another ADS. The funds will be allocated for working capital, acquisitions, and general corporate purposes. Aegis Capital Corp. served as the sole book-running manager for this offering.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced a public offering priced at approximately $8.0 million, consisting of 32 million units of American Depositary Shares (ADS) and associated warrants at a price of $0.25 per ADS. The offering is set to close on December 6, 2022, subject to customary conditions. The net proceeds will be used for working capital, acquisitions, and general corporate purposes. Aegis Capital Corp. is the book-running manager for this offering, conducted under a shelf registration statement declared effective by the SEC.
RedHill Biopharma (Nasdaq: RDHL) announced a proposed underwritten public offering of American Depositary Shares (ADSs) and warrants to purchase ADSs. The Company plans to use net proceeds for working capital, acquisitions, and general corporate purposes. Aegis Capital Corp. is acting as the sole book-running manager. The offering is subject to market conditions and is detailed in a shelf registration statement declared effective by the SEC.
RedHill Biopharma Ltd. (RDHL) has reached a non-binding agreement to sell Movantik to HCR, eliminating its debt obligations. For Q3 2022, RedHill reported net revenues of $17.6 million, a decrease from the previous quarter, with an operating loss of $7.1 million. Prescription growth for Talicia and Movantik stood at 65% and 6.7% year-to-date, respectively. The company has ongoing discussions about opaganib for nuclear radiation injury and COVID-19, while RHB-204 received EU orphan drug status. Cash balance as of September 30, 2022, was $31.4 million.
RedHill Biopharma announced positive preclinical results for opaganib, demonstrating its potential in protecting hematological and kidney functions post total body irradiation (TBI). These findings align with U.S. government-funded data supporting opaganib as a therapeutic for nuclear radiation injuries. The development plan may leverage the Animal Rule, allowing for potential expedited approval without human efficacy studies. Discussions for governmental support are ongoing, while opaganib's further development for COVID-19 and oncology continues, highlighting its versatile pipeline potential.
RedHill Biopharma (Nasdaq: RDHL) has announced accelerated development for opaganib as a potential therapeutic against nuclear radiation injury and for cancer radiotherapy. Recent studies published in the International Journal of Molecular Sciences indicate opaganib may protect normal tissue from radiation damage and enhance survival in irradiated subjects. The drug is an oral, stable, small molecule with a shelf-life exceeding five years, making it suitable for government stockpiling. Development plans include following the Animal Rule for FDA approval and discussions for government support are already underway.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced a non-binding agreement with HCR Collateral Management to transfer its rights in Movantik® (naloxegol) in exchange for cancelling all debt obligations under a Credit Agreement with HCR. RedHill will retain pre-closing liabilities related to Movantik while HCR will assume post-closing liabilities. The definitive agreements are expected to be signed soon, with closing anticipated by year-end, though certainty in completion remains uncertain. The agreement aims to ensure continuity in patient care during the transition.
RedHill Biopharma reported Q2 2022 net revenues of $18.3 million with an operating loss of $9.2 million. As of June 30, 2022, the cash balance stood at $43.2 million. Q3 2022 estimates project revenues between $16.5 million and $18.5 million, with losses between $5.5 million and $7.5 million. Prescription growth continues for Talicia® and Movantik®, with Talicia becoming the most prescribed H. pylori therapy. Ongoing negotiations regarding loan repayments and potential asset sales mark efforts to improve financial standing.
RedHill Biopharma (Nasdaq: RDHL) presented new analyses on Talicia at the Obesity Week Annual Meeting (Nov 1-4, 2022). These analyses indicate that Talicia's efficacy for eradicating H. pylori is not affected by elevated body mass index (BMI) or diabetes. Notably, Talicia achieved an 84% eradication rate compared to 58% for standard therapies. This positions Talicia as a first-line treatment for H. pylori, crucial given that the infection affects ~35% of U.S. adults. Talicia offers a favorable safety profile and demonstrates high intragastric concentrations, supporting its broad applicability in diverse patient populations.